MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Technical Presentation (April 2017)
57 slides from MabVax Therapeutics's technical presentation, Apr 7, 2017
Slide 1: MabVax Therapeutics April 2017 Scientific Presentation
L NASDAQ: MBVX NY, | MabVax therapeutics Clinical Stage Immuno-Oncology Company Developing Unique Human Monoclonal Antibody- Based Products for Difficult to Treat Cancers April 2017 Scientific Presentation David Hansen, President and CEO
Slide 2: Disclaimer
DISCLAIMER Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy and
Slide 3: MabVax Therapeutics Overview
MABVAX THERAPEUTICS OVERVIEW Fully-human antibody discovery platform . € against multiple targets Products discovered from immune responses of cancer patients vaccinated against their solid tumors. Portfolio of antibodies Focused on translation of discoveries into clinical development Introduced thr
Slide 4: Remarkable Clinical and Scientific Progress on Unique Therapeutic and Diagnostic Products
REMARKABLE CLINICAL AND SCIENTIFIC PROGRESS ON UNIQUE THERAPEUTIC AND DIAGNOSTIC PRODUCTS MVT-5873 clinical trial demonstrates ear safety and efficacy MVT-2163 clinical trial demonstrates early safety and specificity MVT-1075 clinical trial authorized by FDA Expansion to other cancers expressing sam
Slide 5: MabVax Has Rich Pipeline of Product Candidates
MABVAX HAS RICH PIPELINE OF PRODUCT CANDIDATES Program MVT-5873 Therapeutic Monotherapy MVT-5873 Therapeutic Combination with soc MVT-2163 PET-Imaging MVT-1075 Radio- immunotherapy HuMab 5B1-ADC. HuMab 5B1- Fe Optimization Additional HuMab Antibodies in Early Development Mi MabVax therepeutice Indic
Slide 6: Summary of Preclinical Data
SUMMARY OF PRECLINICAL DATA Mi MabVax NASDAQ: MBVX therapeutics 6
Slide 7: Sialyl Lewis A as a Viable Target for Cancer Therapeutics
SIALYL LEWIs4 — AS A VIABLE TARGET FOR CANCER THERAPEUTICS ¢# HuMab-5B1 derived from a patient vaccinated with MabVax vaccine licensed from MSKCC CA19-9 detection in patients 4 @ Sialyl Lewis A antigen (SLEA or CA19-9) is the most frequently utilized and only Pancreas 92 validated serum marker for a
Slide 8: Binding of Anti-SLEa mAbs to Multiple Tumor Cells
BINDING OF ANTI-SLE“ MABS TO MULTIPLE TUMOR CELLS A DMS79 2. SSS= Poth Cobety:0en 9 2 00: Gamaty Oat 2 PO Gandy Gam A SCLC ‘ 15B1 r5HI1 |. eS Gee c. Pancreas F \ y & D. Ovary | aif) wt {\ | = wt E Melanoma oF alli, | ¥ Jlilias..___| = iB on B. HT29 Cc. BxPC3 —_ wesiee a —_ 3. 3. % r5B1 os 17E3 | 2 r
Slide 9: HuMab-5B1 Is Highly Specific to SLEa Antigen by Glycan Array Analysis
HuUMaAB-5B1 Is HIGHLY SPECIFIC TO SLE* ANTIGEN BY GLYCAN ARRAY ANALYSIS ‘Consortium for Functional Glycomics i “ * Novel fully-human IgG1 antibody | = ° Exceptional specificity i ce * Very good affinity (0.14nM) , ed * No cross-reactivity with related © ee accents: carbohydrate structures ° CDC and
Slide 10: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers
HUMAB-5B1 ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Potential therapeutic utility extends beyond pancreatic cancer A. Pancreatic ductal adenocarcinoma & B. Colon carcinoma C. Lung adenocarcinoma D. Urinary bladder, mucinous adenocarcinoma E. Colon metastatic to ovary FP. Breast
Slide 11: HuMab-5B1 Is Internalized into Target Cells
HUMAB-5B1 Is INTERNALIZED INTO TARGET CELLS Internalization Occurs Rapidly and Varies Between Cell Lines BxPC3 Capan-2 Mi MabVax therepeutice % Poritve seer eee eee ee ae) Houghton et al., J.Nuc.Med. 2016 Assay Principle The pH sensitive dye pHAb that becomes fluorescent at low pH encountered in end
Slide 12: Non-Clinical Safety Studies Supporting MVT-5873
NON-CLINICAL SAFETY STUDIES SUPPORTING MVT-5873 GLP in vitro tissue cross-reactivity studies with human and cynomolgus tissues ¢ Staining similar in human and cynomolgus providing toxicology species justification @ Staining observed in epithelial cell types and related extracellular mucus-like mater
Slide 13: MVT-5873 Demonstrates Synergistic Anti-Tumor Effect with Chemotherapy
MVT-5873 DEMONSTRATES SYNERGISTIC ANTI- TUMOR EFFECT WITH CHEMOTHERAPY IN MULTIPLE CANCER MODELS Relative Tumor Growth at Day 42 Relative Tumor Volume at Day 52 Gemcitabine/nab-Paclitaxel as Baseline Paclitaxel as Baseline BxPC3 Pancreatic Xenograft Model DMS 79 SCLC Xenograft Model = 2300 ) 3 nutes
Slide 14: MVT-5873 Clinical Program Summary and Interim Data
MVT-5873 CLINICAL PROGRAM SUMMARY AND INTERIM DATA Mi MabVax NASDAQ: MBVX therapeutics 14
Slide 15: MVT-5873 Phase I Trial for PDAC & CA19-9 Positive Cancer
MVT-5873 PHASE I TRIAL FOR PDAC & CA19-9 POSITIVE CANCER Open label, non-Randomized, Dose Escalation/Expansion Study Part 2: Combination with Chemotherapy Part 1: Single Agent Dose Escalation (gemcitabine/nab-paclitaxel) Stage 3 and 4 Patients With Progressive Disease Who Have Failed Other Treatment
Slide 16: Interim MVT-5873 Pharmacokinetics Analysis
INTERIM MVT-5873 PHARMACOKINETICS ANALYSIS PARAMETERS SIMILAR TO OTHER THERAPEUTIC ANTIBODIES ¢# MVT-5873 pharmacokinetics is evaluated in all cohorts ¢ Initial pharmacokinetic analysis includes different schedules of administration were analyzed using a compartment model ¢# Compartmental analysis h
Slide 17: Interim Analysis Shows MVT-5873 Normalizes CA19-9 Levels
INTERIM ANALYSIS SHOWS MVT-5873 NORMALIZES CA19-9 LEVELS IN PANCREATIC CANCER PATIENTS Circulating Levels of Antigen Normalized at Modest Doses of Antibody MVT-5873 Dose and Administration ¢ CA19-9 normalization post MVT-5873 administration appears to be dose dependent % CA19-9 Reduction (>95%, Norm
Slide 18: Clinical Results to Date by Patient
CLINICAL RESULTS TO DATE (03/07/17) BY PATIENT RECIST 1.1 RECIST 1.1 RECIST Lt —_ 9 of 25 Stable at cycles/1 RECIST Assessment Pe Patients 5 of 25 Stable at 4 cycles/2 RECIST Assessments 3 of 25 Stable at 3 cycles/3 RECIST Assessments I oo. 4 5 6 7 8 Time since start of treatment (months) Zmg/kg/eyc
Slide 19: MVT-5873 Adverse Events Observed as a Monotherapy
MVT-5873 ADVERSE EVENTS OBSERVED AS A MONOTHERAPY Number and grade of AEs 40 e S Number . S 40 Miviesvex therapeutics HM Definitely related HM Possibly related MVT-5873 adverse events include early onset infusion reactions and transient increases in liver function tests Infusion reactions are less l
Slide 20: Unmet Clinical Need for Maintenance Therapy
UNMET CLINICAL NEED FOR MAINTENANCE THERAPY ¢ Unmet need to extend and reinforce favorable results with induction therapies — Emerging strategies for long term control include pauses in therapy, re-challenges, and maintenance therapy — Commonly employed strategies are: * Switch to non-cross-resistan
Slide 21: Value of New Maintenance Therapy for Pancreatic Cancer
VALUE OF NEW MAINTENANCE THERAPY FOR PANCREATIC CANCER ¢ Only one comparison product approved for second line therapy: Merrimack’s ONIVYDE — Liposomal irinotecan and used only in combination with fluorouracil and leucovorin — OS improvement to 6.1 mos vs 4.2 mos and PFS improvement to 3.1 mos vs. 1.
Slide 22: MVT-2163 Clinical Program Summary and Interim Data
MVT-2163 CLINICAL PROGRAM SUMMARY AND INTERIM DATA Mi MabVax NASDAQ: MBVX therapeutics 22
Slide 23: MVT-2163 Preclinical Development Efforts Translated into Positive Clinical Results
MVT-2163 PRECLINICAL DEVELOPMENT EFFORTS HAVE TRANSLATED INTO POSITIVE CLINICAL RESULTS ¢ Based on in-depth review of clinical literature and input from thought leaders MabVax developed a rationale for a translational preclinical development plan to define: — Time required to obtain optimal scan ima
Slide 24: MVT-2163 Imaging Compared to Standard PET Agent
MVT-2163 IMAGING COMPARED TO STANDARD PET AGENT Mice orthotopically transplanted with BxPC3-luc pancreatic tumor xenografts JNM Rivers ‘The co-tegistration of FDG-PET and computed Acquired "Zr radiolabed-5B1 antibody (*°Z-5B1) tomography (CT) (left) and planar sections of PET image of the same mouse
Slide 25: 89Zr-HuMab-5B1 Tumor Targeting in Shedding and Non-Shedding Models
89ZR-HUMAB-5B1 TUMOR TARGETING OCCURS IN BOTH SHEDDING AND NON-SHEDDING CA19-9 MODELS DMS79 (SCLC) Does not shed detectable CA 19-9 2h 24h 48h 96h 120h Colo205 (Colon Cancer) High levels of shed antigen ~2300 U/ml for a 250mm? tumor Viola-Villegas, JNucMed 2013 \/ ee NASDAQ: MBVX | 25 W therapeutics
Slide 26: MVT-5873 Pre-Administration Improves MVT-2163 PET Image Quality
MVT-5873 PRE-ADMINISTRATION IMPROVES MVT-2163 PET IMAGE QUALITY Ne ete? }- . Inject radiolabeled ee . ™ . v ee ec: : Tumor Cells. Zr-SB1 Basia ae uptake and Tumor irr Capan-2 Xenografted Mice Interval between injections B5m Binh G4nr 24h No “cold” > a poor contrast ] 2 Inje gs inject unlabeled * ant
Slide 27: Phase I Trial Design of MVT-2163 ImmunoPET Imaging Agent
PHASE I TRIAL DESIGN OF MVT-2163 IMMUNOPET IMAGING AGENT PANCREATIC CANCER AND OTHER CA19-9 MALIGNANCIES Open label, non-randomized, dose escalation/expansion study Patients can roll to MVT-5873 Monotherapy Trial lation and Image Optimization : MVT-216 aero eeiceny Then combin: Additional Safety, PK
Slide 28: Background: Comparable Antibody Therapies for Cancer Diagnosis and Treatment
BACKGROUND: COMPARABLE ANTIBODY THERAPIES FOR CANCER DIAGNOSIS AND TREATMENT 8°Z1-Trastuzumab for metastatic M1J-J591 for hormone Minibody *-Zr-DF IAB2M, breast cancer refractory prostate cancer 50mg pre-administration ‘ / 4 W 4 & 4 < é ¢ 1 day ‘2 days 5 days ie — ba] ena Accumulation occurs over Pr
Slide 29: 89Zr-DFO-HuMab5B1 (MVT-2163) Liver PET Images
89ZR-DFO-HUMAB5B1 (MVT-2163) LIVER PET IMAGES Dose Level: 50mg/4.43 mCi +Patient: Female 158cm/64.2kg Pre-Dose CA19-9 = 2119 IU/mL, Post Dose CA19-9 = 51 IU/mL 1h 20h 44h 141h Mi MabVax NASDAQ: MBVX | 29 therepeutice
Slide 30: Patient Example: MVT-2163 PET Images
PATIENT EXAMPLE: MVT-2163 PET IMAGES LIVER METASTASIS AT HIGH SUV AS EARLY AS Day 1 POST DOSE MVT-2163 PET & Diagnostic CT Image Correlation Demonstrating Target Specificity Liver metastases SUVmax 75.2, Multiple nodes SUVmax 10.2 MVT-5873 47mg then 2h delay time MVT-2163 PET PET / Cr | 20h 141h Dia
Slide 31: MVT-2163 Biodistribution
MVT-2163 BIODISTRIBUTION COMPARABLE WITH j591 AND JAB2M MINIBODY TRACERS 3.0 = OIAb2M. ao @J591 250 =5B1 (0) S o o ° fa] Sag 3° ao 2 ¢ 00 alitit alidal Ss & & eS ss ss YE SEPE Ly my rs ~ S M MabVax Patient #9 NASDAQ: MBVX | 31 therapeutics
Slide 32: Significant Accumulation of Antibody on Targeted Cancer
SIGNIFICANT ACCUMULATION OF ANTIBODY ON TARGETED CANCER MVT-2163 Accumulates on Target without interference by CA19-9 Levels Patient administered 3 mg MVT-2163 Patient administered 3 mg MVT- (no MVT-5873 loading dose) 2163 (47 mg MVT-5873 loading dose) 3 ry % 30 as Eos ? 820 % 3% bn =. $10 SOmPA Nod
Slide 33: MVT-2163 Product Opportunity
MVT-2163 PRODUCT OPPORTUNITY MVT-2163 images tumor lesions not identified by diagnostic CT Staging newly diagnosed PDAC patients for surgery is limited by CT resolution — Only 20% deemed eligible for surgery and majority found inoperable during surgery — Problem: Incomplete disease dissemination ide
Slide 34: MVT-1075 Program Summary and Product Opportunity
MVT-1075 PROGRAM SUMMARY AND PRODUCT OPPORTUNITY Mi MabVax NASDAQ: MBVX therapeutics 34
Slide 35: MVT-1075 Is Designed to Attack Primary Tumor and Metastatic Sites
MVT-1075 Is DESIGNED TO ATTACK PRIMARY TUMOR AND METASTATIC SITES Attribute HuMab-5B1 Antibody CA19-9 is validated target for PDAC Effective Payload Lutetium radionuclide (7Lu) Multi-cell effective range for tumor cell killing Loading dose pharmacokinetics well established by MVT-2163 MabVax therape
Slide 36: MVT-1075 Designed to Attack Primary Tumor and Metastatic Sites and Enhance Cell Death
MVT-1075 Is DESIGNED TO ATTACK PRIMARY TUMOR AND METASTATIC SITES AND ENHANCE CELL DEATH Highly specific HuMab- 5B1 antibody conjugated to radionuclide (177Lu) MVT-2163 Phase I results demonstrate significant accumulation on tumor Rapid and significant internalization of antibody-radionuclide oN Eff
Slide 37: MVT-1075 Radioimmunotherapy Preclinical Studies Demonstrate Tumor Growth Suppression
MVT-1075 RADIOIMMUNOTHERAPY — PRECLINICAL STUDIES DEMONSTRATE SUBSTANTIAL TUMOR GROWTH SUPPRESSION AND TUMOR REGRESSION Biodistribution of 7 Lu-CHX-A”-DTPA-5B1 fs 277LU-CHX-A”-DTPA-5B1 © Control (PBS) = 5B1 0 > 130 2 = 300uGi 120 5 0) & 450uci 110: < wth 3 40 3 N=8 for all groups FI 80 i > 3 3 2 60.
Slide 38: MVT-1075 HuMab-5B1 Radioimmunotherapy Orthotopic PDAC Model
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY ORTHOTOPIC PDAC MODEL DEMONSTRATES TUMOR REGRESSION BO Pre-treatment Post-treatment Collaboration with Jason S. Lewis, Ph.D. Member, Memorial Sloan-Kettering Cancer Center, Mi Vice Chairman & Chief Attending, Department of Radiology MabVax NASDAQ: MBVX 38
Slide 39: Manufacturing, Quality, Distribution Established for Clinical Program
MANUFACTURING, QUALITY, DISTRIBUTION ESTABLISHED FOR CLINICAL PROGRAM AND PATHWAY FOR COMMERCIALIZATION ¢@ MVT-1075 manufactured on a per patient basis ¢ Manufacturing established at experienced cGMP third party site @ Produced from a bulk conjugate intermediate as unit-of-use vials @ Process simila
Slide 40: Phase I Trial of MVT-1075 Radioimmunotherapy
PHASE I TRIAL OF MVT-1075 RADIOIMMUNOTHERAPY FOR PANCREATIC AND OTHER CA19-9 MALIGNANCIES Open label, Non-randomized, Dose Escalation Safety Study Establish Safety, Tolerability, Dosimetry & RP2D ration Phase I Dose E ion and Expansion onal dose udy design to determine MTD Histologically confirmed,
Slide 41: MVT-1075 Unique Product with Significant Value Proposition
MVT-1075 UNIQUE PRODUCT WITH SIGNIFICANT VALUE PROPOSITION Single doses of MVT-1075 demonstrate tumor regression in Compelling preclinical animal models of PDAC MVT-2163 clinical data have establish dosimetry, target specificity and high SUV values Prognosis for PDAC still poor. Must target primary
Slide 42: MVT-1075 Product Opportunity
MVT-1075 PRODUCT OPPORTUNITY ¢ Reduce disease burden by making more patients eligible for surgery — Given to newly diagnosed patients either before or after chemotherapy to reduce primary tumor size/spread and eliminate metastatic sites ¢ Applicable for multiple cancer types that are positive for CA
Slide 43: Value Proposition for a New Radioimmunotherapy for Pancreatic Cancer
VALUE PROPOSITION FOR A NEW RADIOIMMUNOTHERAPY FOR PANCREATIC CANCER ¢ Algeta’s Xofigo for castration-resistant prostate cancer — Xofigo (radium Ra 223) is radiotherapeutic alpha particle emitting product — Approved in US in May 2013 and EU in November 2013 — Development and commercialization deal w
Slide 44: HuMab 5B-1 ADC Program Summary and Product Opportunity
HUMAB 5B-1 ADC PROGRAM SUMMARY AND PRODUCT OPPORTUNITY Mi MabVax NASDAQ: MBVX therapeutics 44
Slide 45: HuMab-5B1-Based Antibody Drug Conjugate (ADC)
HUMAB-5B1-BASED ANTIBODY DRUG CONJUGATE (ADC) HuMab-5B1 has ideal characteristics for ADC ¢ Antibody is readily internalized ¢ Large number of targets on each cell ¢ Established targeting specificity and affinity ¢ Clinical validation ¢ Acceptable toxicology profile ¢ Multiple linker/toxin combinati
Slide 46: Extensive ADC Evaluation
EXTENSIVE ADC EVALUATION ¢ Multiple toxins evaluated — Saporin conjugated secondary antibody (Sawada et al. 2011) — Amanitin — MMAE, MMAF ¢ Developed internalization assay — Indirect or direct conjugated pH sensitive fluorophore (pHAb; Promega) ¢ Multiple linker technologies evaluated including — Ma
Slide 47: HuMab-5B1 Is Internalized into Target Cells
HUMAB-5B1 Is INTERNALIZED INTO TARGET CELLS Internalization Occurs Rapidly and Varies Between Cell Lines Assay Principle ¢ The pH sensitive dye pHAb that becomes fluorescent at low pH % Posttve BxPC3 : ! encountered in endosomes is conjugated to MVT-5873 or anti- human F(ab),. ¢ The percentage of fl
Slide 48: Activity of Site-Specific MMAE-ADCs
ACTIVITY OF SITE-SPECIFIC MMAE-ADCs In vitro cytotoxicity of chemoenzymatic site specific labeled MMAE-ADCs (Houghton et al., PNAS 2016) B-1,4-Galactosidase GalT(¥289L) DIBO-Toxin % Ns Ny Ny Unconjugated Ab Azide-Activated Ab Conjugated ADC (stable for long-term storage) DOL =3.4 IC50 (nM) SCLC Tcel
Slide 49: Cytotoxicity of 5B1 ADCs on Tumor Cell Lines
CYTOTOXICITY OF 5B1 ADCs ON TUMOR CELL LINES In vitro cytotoxicity of amanitin-ADCs on various cell lines Prat: BxPcs Plate 2: Capan2 Gu ‘ {cells ste’ |581-ADc| ADC : ; | { |colo20s | ++ | 0.159 | 1746 z ’ perme gs h, na [execs + | 2514 | 186.7 i vefmaite : fetes \capan-2 ++ | 0.043 | 45.2 5 3 jurka
Slide 50: Efficacy in a Human Pancreatic Xenograft Model
EFFICACY IN A HUMAN PANCREATIC XENOGRAFT MODEL HuMab-5B1 Antibody Drug Conjugate In Vivo Data (BxPC3 xenografts) Lysine Conjugated Amanitin Linker Optimization Study Demonstrates Demonstrates Efficacy Spectrum of Efficacy Mean Tumor Volume [600.00 _>—________-_ -»- PBS. iad “®ADCI 400.00 “eape2 300.
Slide 51: Market Opportunity for HuMab 5B1
MARKET OPPORTUNITY FOR HUMAB 5B1 — REPRESENTS POTENTIAL NEW TREATMENTS FOR MULTIPLE CANCERS Pancreatic Colon & Rectum Small Cell Lung Cancer Stomach Mi MabVax therepeutice 53,070 134,490 30,143 26,370 Deaths Yr /Y ul 41,780 7.7% 49,119 65% 20,100 14% 10,730 31% ' Global Data Disease Reports portunit
Slide 52: Partnering Discussions
PARTNERING DISCUSSIONS ¢ Active discussions with potential partners under CDA in progress. Multiple opportunities ¢ Antibody as targeting vehicle for development of a bi-specific, ADC or CAR-T product — Multiple domestic and Asian companies — Multiple indications ¢ Radioimmunotherapy product — Multi
Slide 53: Key Milestones for HuMab5B1 Development Programs
Key MILESTONES FOR HUMAB5B1 DEVELOPMENT PROGRAMS FOR 2016 AND 2017 Program MVT-5873 Therapeutic Monotherapy MVT-5873 Therapeutic Combination with Chemo MVT-2163 PET Imaging MVT-1075 Radio- Immunotherapy HuMab-5B1 ADC Miviesvex therepeutice 1H2016 VY Initiate dose escalation safety Phase I Trial Init
Slide 54: Focused on Building Shareholder Value Near Term
FOCUSED ON BUILDING SHAREHOLDER VALUE NEAR TERM 1. Encouraging data emerging from two clinical trials 2. Complete MVT-5873 phase Ia therapeutic clinical study and present data early in 2017. Define recommended phase II dose (RP2D) 3. Launch Phase 5873 phase Ib POC for maintenance treatment in PDAC 4
Slide 55: Robust Intellectual Property
ROBUST INTELLECTUAL PROPERTY 14 issued patents and 3 pending applications in the U.S. ¢ 13 issued US patents and 1 pending US application covering monovalent and polyvalent vaccines, methods of manufacture, methods of use ¢ 1 issued US patent and 2 pending US applications covering monoclonal antibod
Slide 56: Strong Management Team and Board of Directors
STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS anageme J. David Hansen Founder, President & CEO Board Member Philip Livingston, M.D. Founder & Chief Science Officer Gregory Hanson, CMA Chief Financial Officer Wolfgang Scholz, Ph.D. Founder & Vice President Antibody Discovery Paul Maffuid, Ph.D. Execu
Slide 57: Company Contacts
Mi MabVax therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer Company Contacts J. David Hansen Gregory P. Hanson CMA MBA President and CEO Chief Financial Officer dhansen@mabvax.com gregoryhanson@mabvax.com 858-500-8455 858-500-8457 Mi MabVax NASDAQ: MBVX | 57 t
MabVax Therapeutics Holdings — Technical Presentation (April 2017) on 6ix